Funding round
Nimbus Therapeutics Growth
Reported as "Growth Equity"
Nimbus Therapeutics, which works in precision small molecule drug discovery in Boston, raised $105M in a Growth round announced on 13 Jul 2021, led by BVF Partners L.P.. 8 firms took part, 3 of them already investors. It is Nimbus Therapeutics' fifth venture round on record; the one before was a Growth in Oct 2020.
$105M
Amount raised
Not disclosed
Post-money valuation
8
Investors
1 lead
Valuation
What this round says about the price
Nimbus Therapeutics did not disclose a valuation in this round. It came 9 months after Nimbus Therapeutics' Growth. It is 18% of the $569M Nimbus Therapeutics has raised in the venture rounds on record. Nimbus Therapeutics raised again 14 months later: a Growth round of $125M in Sep 2022.
Nimbus Therapeutics' funding rounds
Nimbus Therapeutics has 7 venture rounds on record. This one is highlighted.
- Seed 1 Mar 2011 $1.5M
- Series A 28 Jun 2011, led by Atlas Venture, SR One and Lilly Ventures $24M
- Series B 18 Mar 2015, led by Pfizer Venture Investments and Lightstone Ventures $43M
- Growth 14 Oct 2020, led by RA Capital $60M
- Growth this round 13 Jul 2021, led by BVF Partners L.P. $105M
- Growth 12 Sep 2022, led by Bain Capital Life Sciences and SV Health Investors $125M
- Growth 6 Sep 2023, led by GV, SR One and Atlas Venture $210M
Investors
Who put money in
BVF Partners L.P. led the round with 7 other firms. BVF Partners L.P., RA Capital and Atlas Venture had backed Nimbus Therapeutics before.
Lead investor
- BVF Partners L.P. existing investor
Also in the round
- backs 109 venture-backed companies existing investor
- backs 43 venture-backed companies existing investor
- Access Biotechnology new investor
- backs 3 venture-backed companies new investor
- Logos Capital new investor
- Surveyor Capital new investor
- large alternative asset manager new investor
Joined the board: Sam Huang (BVF Partners L.P.).
Use of proceeds
What the money is for
According to the announcement, the money goes to product development, scaling operations and working capital.
- Product development
- Scaling operations
- Working capital
Comparable rounds
How it compares
23 Growth rounds in Pharmaceutical Products within a year either side disclosed an amount; the median was $55M, and this round was 1.9 times the median. The closest in time, other companies' Growth rounds in Pharmaceutical Products:
| Company | Announced | Amount | Post-money | Led by |
|---|---|---|---|---|
| Pharmaceutical Products | 27 Jul 2021 | $65M | not disclosed | Mammoth Scientific |
| Pharmaceutical Products | 13 Jul 2021 | $31M | not disclosed | not named |
| Pharmaceutical Products | 21 Jul 2021 | $25M | not disclosed | not named |
| Pharmaceutical Products | 22 Jun 2021 | $42M | not disclosed | UCB Ventures and The Column Group |
| Pharmaceutical Products | 16 Jun 2021 | $32M | not disclosed | DSM Venturing |
| Pharmaceutical Products | 29 Jun 2021 | $29M | not disclosed | not named |
| Pharmaceutical Products | 14 Sep 2021 | $133M | not disclosed | Fidelity Management and Research and Fidelity Management & Research Company |
| Pharmaceutical Products | 27 Sep 2021 | $60M | not disclosed | not named |
Sources
Where this comes from
Reported by 3 sources. The deal data marks this round as not yet confirmed by an official announcement. Unconfirmed
Questions
Frequently asked
How much did Nimbus Therapeutics raise in its Growth round?
Nimbus Therapeutics raised $105M in its Growth round, announced in Jul 2021.
Who led Nimbus Therapeutics' Growth round?
BVF Partners L.P. led it, with RA Capital, Atlas Venture, Access Biotechnology, Commodore Capital and Logos Capital and 2 more.
What was Nimbus Therapeutics' valuation at the Growth round?
It was not disclosed.
How does it compare with other Growth rounds in Pharmaceutical Products?
23 Growth rounds in Pharmaceutical Products within a year either side disclosed an amount; the median was $55M, and this round was 1.9 times the median.
Did Nimbus Therapeutics raise again after this round?
Yes: a Growth round in Sep 2022 of $125M.